NEW INDICATIONS

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

Web Exclusives - FDA Oncology Update

On July 9, 2021, the FDA accelerated the approval of a new indication for daratumumab and hyaluronidase-fihj (Darzalex Faspro; Janssen Biotech), in combination with pomalidomide (Pomalyst; Bristol Myers Squibb) and dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous line of therapy, including lenalidomide (Revlimid) or a proteasome inhibitor.

Daratumumab and hyaluronidase, as well as pomalidomide, are each already approved for the treatment of patients with multiple myeloma, alone or in combination with other drugs.

This new indication was based on the results of the APOLLO study, an open-label, active-controlled clinical trial of 304 patients who were randomized in a 1:1 ratio to daratumumab and hyaluronidase plus pomalidomide and dexamethasone or to pomalidomide and dexamethasone alone.

The primary end point was progression-free survival (PFS). The median PFS was 12.4 months in the daratumumab and hyaluronidase plus pomalidomide and dexamethasone arm versus 6.9 months with pomalidomide and dexamethasone alone (hazard ratio, 0.63; 95% confidence interval, 0.47-0.85; P = .0018), a 37% risk reduction of disease progression or death with the 3-drug versus the 2-drug combination.

The most common (≥20%) adverse reactions with the 3-drug combination were fatigue, pneumonia, upper respiratory tract infection, and diarrhea.

Related Items
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
Online First published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
Online First published on November 3, 2023 in FDA Oncology Update
Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation
Online First published on November 3, 2023 in FDA Oncology Update
FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma
Online First published on November 3, 2023 in FDA Oncology Update
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma
Online First published on November 3, 2023 in FDA Oncology Update
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer
Online First published on November 3, 2023 in FDA Oncology Update
Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program
Online First published on November 3, 2023 in FDA Oncology Update
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
JHOP - October 2023 Vol 13, No 5 published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
JHOP - October 2023 Vol 13, No 5 published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
JHOP - October 2023 Vol 13, No 5 published on September 8, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: